Source-grounded facts extracted from Beam Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Beam Therapeutics Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-03 meeting.
“Proposal 3 – The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following votes: For Against Abstentions Broker Non-Votes 71,546,749 985,066 273,533 13,419,659”
Beam Therapeutics Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
“Proposal 2 – The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 was ratified, based on the following votes: For Against Abstentions 85,754,272 165,746 304,989”
Beam Therapeutics Inc. shareholders approved Election of three Class III directors at the 2026-06-03 meeting.
“Proposal 1 – The following nominees were elected as Class III directors to serve on the Company’s board of directors until the Company’s 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes: Nominee For Against Abstentions Broker Non-Votes John Evans 71,684,417 864,042 256,889 13,419,659 John Maraganore, Ph.D. 64,846,080 7,701,591 257,677 13,419,659 Christi Shaw 65,652,959 6,893,102 259,287 13,419,659”
Beam Therapeutics Inc. reported financial results for quarter ended March 31, 2026.
“On May 7, 2026, the Company issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Beam Therapeutics Inc. terminated License Agreement with Bio Palette Co., Ltd. (effective 2026-03-02).
“Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) mutually terminated the License Agreement by and between the Company and Bio Palette dated March 27, 2019 (the “License Agreement”)”
Beam Therapeutics Inc. incurred term loan of up to $500 million with Sixth Street Lending Partners at 3-month Secured Overnight Financing Rate (SOFR) plus 6.50% (subject to a 1.00% f maturing February 24, 2033.
“On February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of up to $500 million (the “Credit Facility”), consisting of (i) an initial draw of $100 million on the Closing Date,”
Beam Therapeutics Inc. entered into Financing Agreement with Sixth Street Lending Partners, as administrative agent and collateral agent valued at $500 million (effective 2026-02-24).
“On February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders.”
Beam Therapeutics Inc. entered into Standby License Agreement with Kobe University and Bio Palette Co., Ltd. (effective 2026-02-09).
“on February 9, 2026, the Company entered into a standby license agreement (the “Standby License Agreement”) with Kobe and Bio Palette.”
Beam Therapeutics Inc. completed a disposition involving Bristol-Myers Squibb Company for $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration (closed 2025-12-08).
“of Orbital common stock, which represented a fully diluted ownership stake of approximately 17%. At the closing of the Acquisition, such shares were cancelled and converted into $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration upon the release, if any, of certain escrows. The”
John Evans was appointed as Principal Financial and Accounting Officer at Beam Therapeutics Inc..
“Effective upon Ms. Burrell’s resignation, John Evans, the Company’s Chief Executive Officer and a member of the Company’s board of directors, was appointed Principal Financial and Accounting Officer of the Company.”
Terry-Ann Burrell resigned as Chief Financial Officer and Treasurer at Beam Therapeutics Inc..
“Terry-Ann Burrell notified Beam Therapeutics Inc. (the “Company”) of her decision to resign as Chief Financial Officer and Treasurer of the Company, effective August 9, 2024, to pursue other opportunities.”
Beam Therapeutics Inc. reported first quarter 2024 results: net income ($98.7 million), EPS ($1.21).
“Net loss was $98.7 million for the first quarter of 2024, or $1.21 per share, compared to $96.5 million for the first quarter of 2023, or $1.33 per share.”
Beam Therapeutics Inc. reported the year ended December 31, 2023 results: net income net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 202, EPS $1.72 per share.
“net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 2023”
Beam Therapeutics Inc. reported the fourth quarter of 2023 results: net income Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share,, EPS $1.77 per basic share and $1.73 per diluted share.
“Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share, for the fourth quarter of 2023”
Christi Shaw was elected as member of the Board at Beam Therapeutics Inc..
“On December 13, 2023, the Board of Directors (the “Board”) of Beam Therapeutics Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from seven to eight members and elected Christi Shaw as a member of the Board.”
Beam Therapeutics Inc. reported financial results for the third quarter 2023.
“On November 8, 2023, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023.”
Beam Therapeutics Inc. completed a disposition involving Eli Lilly and Company for $200 million upfront payment and $50 million equity investment (closed 2023-10-27).
“(“Beam” or the “Company”) entered into a Transfer and Delegation Agreement (the “Transfer Agreement”) with Eli Lilly and Company (“Lilly”), pursuant to which Lilly acquired, as of the Execution Date, certain assets and other rights under Beam’s amended collaboration and license agreement (the “Collaboration Agreement”) with Verve Therapeutics, Inc.”
Beam Therapeutics Inc. announced a restructuring with charges of approximately $6.6 million affecting not explicitly stated per segment, but described as portfolio prioritization and strategic restructuring of Beam Therapeutics (approximately 100 positions, or about 20% of its workforce).
“the Company expects to reduce its employee headcount by approximately 100 positions, or about 20% of its workforce. The Company expects to incur one-time costs of approximately $6.6 million in the fourth quarter of 2023 in connection with the workforce reduction. These costs consist primarily of cash expenditures related to severance payments. The Company estimates”
Beam Therapeutics Inc. reported financial results for the quarter ended June 30, 2023.
“On August 8, 2023, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2023.”
Beam Therapeutics Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-06 meeting.
“Proposal 3 – The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following votes: For Against Abstentions Broker Non-Votes 47,040,443 1,996,717 41,788 11,303,038”
Beam Therapeutics Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-06 meeting.
“Proposal 2 – The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was ratified, based on the following votes: For Against Abstentions 60,120,184 31,889 229,913”
Beam Therapeutics Inc. shareholders approved Election of Class III directors at the 2023-06-06 meeting.
“Proposal 1 – Each of the following nominees were elected as Class III directors to serve on the Company’s board of directors until the Company’s 2026 annual meeting of stockholders, and until their respective successors have been duly elected and qualified, based on the following votes: Nominee For Against Abstentions Broker Non-Votes John Evans 48,704,446 250,291 124,211 11,303,038 John Maraganore, Ph.D. 41,623,856 7,441,072 14,020 11,303,038”
Beam Therapeutics Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $96.5 million for the first quarter of 2023, or $1.33 per share, EPS $1.33 per share.
“Net loss was $96.5 million for the first quarter of 2023, or $1.33 per share, compared to $69.2 million for the first quarter of 2022, or $1.01 per share.”
Beam Therapeutics Inc. amended Amendment No. 2 to the Sales Agreement with Jefferies LLC valued at up to $300,000,000 (effective 2023-05-10).
“On May 10, 2023, the Company and Jefferies entered into Amendment No. 2 to the Sales Agreement (“Amendment No. 2” and together with the Amended Sales Agreement, the “Further Amended Sales Agreement”) to provide for an increase in the aggregate offering amount under the Amended Sales Agreement, such that as of May 10, 2023, the Company may offer and sell additional shares of Common Stock having an aggregate offering price of up to $300,000,000 (the “Additional Shares” and together with the “Initial Shares”, the “Shares”) under the Further Amended Sales Agreement.”
Beam Therapeutics Inc. reported the fourth quarter of 2022 results: net income Net loss attributable to common stockholders was $38.3 million, or $0.54 per share, for the fourth quarter of 2022, EPS $0.54 per share. Guidance reaffirmed.
“issued a press release announcing the Company’s financial results for the quarter ended December 31, 2022.”
Beam Therapeutics Inc. reported financial results for the quarter ended September 30, 2022.
“On November 7, 2022, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2022.”
John Maraganore was elected as Director at Beam Therapeutics Inc..
“On November 5, 2021, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from six to seven members and elected John Maraganore, Ph.D., as a member of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.